Home
>
National Drug Code (NDC)
>
TYKERB
TYKERB - 0173-0752-00 - (lapatinib)
Drug Information of TYKERB
| Product NDC: | 0173-0752 |
| Proprietary Name: | TYKERB |
| Non Proprietary Name: | lapatinib |
| Active Ingredient(s): | 250 mg/1 & nbsp; lapatinib |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of TYKERB
| Product NDC: | 0173-0752 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022059 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20070316 |
Package Information of TYKERB
| Package NDC: | 0173-0752-00 |
| Package Description: | 150 TABLET in 1 BOTTLE (0173-0752-00) |
NDC Information of TYKERB
| NDC Code | 0173-0752-00 |
| Proprietary Name | TYKERB |
| Package Description | 150 TABLET in 1 BOTTLE (0173-0752-00) |
| Product NDC | 0173-0752 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | lapatinib |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20070316 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | LAPATINIB DITOSYLATE |
| Strength Number | 250 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
